Synthesizing Knowledge by Exploiting Diverse Data Sources: From Microblogs to Patents

David Milward

ICIC, October 2011



Range Of Application Areas



Example Data Sources

- External Data
 - Social Media
 - Scientific Literature
 - Conference Abstracts
 - Patents
 - Clinical Trials
- Internal Data
 - SharePoint repositories
 - Excel spreadsheets
 - Project reports
 - Electronic Health Records



Mining Social Media

To provide actionable information from public sentiment



What is being said about our brands? How are the messages being relayed?

Who are the key opinion leaders?

Which sites are influencing our consumers?



What are people saying about us and our competitors?



Microblogs: Twitter





Natural Language Processing (NLP)

- Find and extract patterns, not just keywords
- Capturing the 1000s of ways people say the same thing
- For example: how do people express that they are going to get a flu vaccine vs. not get one?

	my flu shot				
Just not	a flu shot				
bust got	the flu shot				
l got	my first flu shot				
act	my seasonal flu shot				
goi	flu shot				
Getting	my Flu shot				
Got	a Flu shot				
just got	a flu vaccine				
l just got	a flu vaccine shot				
	an H1N1 shot				
' i got	el flu shot				
Had	her flu shot				
getting	her h1n1 vaccine				
' I'm getting	her swine flu jab				
	i flu shot				
	my 1st flu shot				
	my annual flu shot				
	my company flu shot				
	my flu jab				
	my flu mist				
	my flu mist!				



Refining Sentiment via Context: UK Elections

- Accurate prediction of UK Election Results based on sentiment trends
- What we counted as positive



Great point from Nick on funding - the #labservative have not ... @miwk ... of people - We think Clegg is winning 5/4, Cameron 7/4... @nicholasgrundy Nick clegg seems to be doing well in the debate. ... @nillan

• What we did not count as positive

Don't like the way Clegg talks to the camera all the time #leadershipdebate ... @Fertzy ... look a little bit like Gordon Brown in a few years? ... @hungrypumpkin

i don't like nick clegg's black shoes with his navy suit. ... @kylieg85

I don't like Gordon Brown at all. ... @MysticOnion

Cameron didn't like Brown's dig about the anti-Labour posters. ... @phillavelle

If cameron wins this years election I am migrating out of Britain... @_Christianah_

Don't think DC has come out well from this so far. ... @adrian_edgar



Who will get a vaccine, and finding their influences



Categorizing by Topic and by Statement

Drug only	entity: basic	(empty)		Doc	Hit
Company		Gene testing war looms for AstraZeneca heart drug	▶ 67	<u>470</u>	1 Gene testing war looms for AstraZeneca heart drug: By Ben Hirschler, European Pharmaceuticals Correspondent STOCKH http://bit.ly/a8QPIA
	Jobs	AstraZeneca: Pharmaceutical Sales Specialist	253	<u>19</u>	1 AstraZeneca: Pharmaceutical Sales Specialist - Hos (Asheville, NC) http://bit.ly/9Nrw36 #Astrazenecajobs #Jobs #TweetMyJOBS

ltem	Category	Statement		Doc		Hit
Company		Pfizer seeking to boost animal health sales	▶ 34	1023	1	Pfizer seeking to boost animal health sales - Yahoo/AP Fri, 09/17/10 - 7:18 am http://is.gd/feTRY
	Jobs	#job Administrative Assistant - Pfizer - New York	2	<u>764</u>	1	#job Administrative Assistant - Pfizer - New York, NY http://bit.ly/b18uhz
	✓lipitor	Pfizer revenue was more than \$50B lastyear	▶ 4	<u>1371</u>	1	Pfizer revenue was more than \$50B lastyear just for selling Viagra and Lipitor. Damn this business so sexy :) http://bit.ly/cEv2VK

- Many Tweets or newsfeed statements are duplicates, but comparing characterby-character does not show this
- Here we are categorizing by topic e.g. jobs or drug, and using NLP to cluster by the messages to allow faster reviewing



Mining MEDLINE

Drug Repurposing

Target ID and Prioritization



Biomarker Discovery



Gene Profile

• Gathers together information relevant for a specific gene from multiple documents

Gene	Entity Type	Entity	Qualifier		Doc		Hit
CTLA4	▶ chemical	▶ Ipilimumab	affected by	▶ 4	20593249	1	Ipilimumab acts as a T-cell potentiator via blockade of cytotoxic T-lymphocyte antigen- 4, a negative regulator of T-cell activation.
	▶ disease	Autoimmune Disease		▶2	20418973	1	One of the candidate genes which has a strong association with several autoimmune diseases is CTLA-4 gene located in chromosome 2q33 region.
	gene/protein	anti-CD152	antibody	1	21074064	1	The complex interaction between antigen- presenting cells and T lymphocytes as an immune response is strongly affected by anti-CD152 (cytotoxic T-lymphocyte antigen -4, CTLA-4)-antibodies.
	mutation	+49 A/G		1	<u>19345707</u>	1	The single nucleotide polymorphism (SNP) +49 A/G of the CTLA-4 gene alters intracellular distribution of CTLA-4, interleukin-2 production, and, as a consequence, T-cell proliferation.
	▶ pathway/process	Autoimmune Process		1	<u>19345707</u>	1	Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases.



Relating Genes to Disease



Mining Conference Proceedings

To provide actionable information about competitors or activities of potential acquisition targets



Gather information for internal customers



Identify new/novel areas of research



Find other companies / researchers working in the same area



Conference Proceedings

• Creating an itinerary for poster viewing

Event Day	Poster No.	Stream	Gene		Doc		Hit
▼Day 1	174	FC05	AGT	1	<u>174</u>	1,	Angiotensin II type 2 receptor activation modulates insulin receptor signalling pathways in adult sensory neurons <mark>Narumi Hobara</mark> , (Japan), N Hashikawa, Y Zamami, H Kawasaki, <mark>C Yutani</mark>
	272	FC09	STAT6	1	272	11	nhibitory effect of AS1517499, a novel STAT6 inhibitor, on antigen-induced airway hyperresponsiveness in mice <mark>Yoshihiko Chiba</mark> , (Japan), M Todoroki, Y Nishida, M Tanabe, <mark>M Misawa</mark>
	295	FC09	AGTR1	1	<u>295</u>	1	Effect of AT1 receptor blockade on the antioxidants enzymes activities in an experimental model of periodontal disease induced by ipopolysaccharide in the rat Maria del Rosario Garrido, (Venezuela), MG Matos, JA Silva, Y Mathison, A Israel
	303	FC09	ROCK1	1	<u>303</u>	1	Rho-kinase inhibitors augment anesthetics-induced relaxation in rat airway smooth muscle <mark>Motohiko Hanazaki</mark> , (Japan), A Kohjitani, S Mizobuchi, K Morita, H Sakai, Y Chiba, <mark>M Misawa</mark>
	306	FC09	APOE	1	<u>306</u>	1	Relation of HSPs expression and formation of atherosclerotic lesions in the aorta of <mark>ApoE-deficient</mark> mice <mark>Naoya Hashikawa</mark> , (Japan), N Hobara, <mark>C Yutani</mark>
	439	▶ W19	AGT	1	<u>439</u>	1,	Angiotensin II type 1 (AT1) receptor blocker, telmisartan, protects brain damage induced by ischemia and amyloid-β injection partly due to PPAR-γ activation Masaki Mogi, (Japan), J Iwanami, K Tsukuda, <mark>M Horiuchi</mark>
✓Day 2	127	FC05	AGTR1	1	<u>608</u>	1	Role of AT1 receptor on the CNS insulin signalling in animal model of type 2 diabetes Mariella Pastorello, (Venezuela), A Israel
	259	FC09	AGT	1	<u>740</u>	1,	Angiotensin II induces hyperresponsiveness of bronchial smooth muscle via an activation of p42/44 ERK in rats <mark>Hiroyasu Sakai</mark> , (Japan), Y Chiba, M Hanazaki, <mark>M Misawa</mark>
]	265	FC09	RHOA	1	<u>746</u>	1	nvolvements of RhoA geranylgeranylation in the pathogenesis of allergic bronchial asthma Aya Shibuya, (Japan), S Sato, Y Chiba, M Misawa
	287	FC09	SRC	1	<u>768</u>	1	Possible involvement of <mark>Src</mark> family kinases in the rat bronchial smooth muscle contraction <mark>Yu Watanabe</mark> , (Japan), H Sakai, Y Chiba, <mark>M Misawa</mark>
✓Day 3	265	FC15	AGTR1	1	1240	1	Role of AT1 receptor and NAD(P)H oxidase in the pressor resonse and hypothalamic antioxidant enzymes activity induce by forced mmobilization in rats Anita Israel, (Venezuela), J Silva, S DeJesus, I Medina, MR Garrido
	273	FC15	AGT	1	<u>1248</u>	1	Chronic intake of RWPs improves EDHF-mediated relaxation in the mesenteric artery of old rats: Role of angiotensin II and AT1 receptors N Khodja, T Chataigneau, C Auger, Valerie B Schini-Kerth (France)
	385	FC16	nitric oxide synthase	1	<u>1360</u>	1,	Aronia juice, a polyphenol-rich berry juice, induces redox-sensitive activation of endothelial <mark>nitric oxide synthase</mark> and relaxation in porcine coronary arteries J-H Kim, C Auger, T Chataigneau, <mark>Valerie B Schini-Kerth</mark> , (France)
▼Day 4	104	FC12	AGT	1	1528	1,	Angiotensin II inhibites IKr /hERG channels through protein kinase C <mark>Yuhong Wang</mark> , (PR China), J Xu, X Chen, <mark>Y Xu</mark>
	254	FC15	AGT	1	<u>1678</u>	1	Role of AT1 and AT2 receptor and NAD(P)H oxidase on <mark>angiotensin II-stimulated</mark> antioxidant enzymes activity in the rat hypothalamus <mark>Jose Silva</mark> , (Venezuela), M Pastorello, S De Jesus, MG Matos, MR Garrido, <mark>A Israel</mark>



Conference Proceedings – Presenter Network





Mining Patent literature





Patent Grants Distribution by Disease (Sample)



Patent Applications and Grants: Companies vs. Diseases



Finding Inhibition Information in Patents

IC50	<	20	nM		<u>123</u>	1	(IC 50 < 20 nM, with several having IC
IC50		400	nM		<u>123</u>	1	inhibits GST PI-I with an IC 50 of approximately 400 nM.
IC50	<	800	nM		<u>126</u>	2	binding of IgG-Fc with an <mark>IC 50</mark> of <mark>less than</mark> about 800 <mark>nM</mark> , less than about 600
IC50		800	nM		<u>126</u>	1	embodiments, antibodies have an <mark>IC 50</mark> value of <mark>800 nM</mark> , 400 nM, 100
IC50	>	100	microM		<u>131</u>	1	in detergent-disrupted microsomes with an IC 50 of about > 100 µM indicating a high degree of
IC50		0.06	microg	ml	<u>131</u>	1	of semi-pure compound having an IC 50 of 0.06 µg/ml.



Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia (CML) demonstrate that many patients with advanced stage disease respond initially but then relapse.

Alternatively, if expansion of the leukemia clone is independent of Bcr-Abl, then signaling through the Bcr-Abl pathway should remain impaired by STI-571.

(IC 50 =concentration of STI-571 required to reduce CRKL phosphorylation by 50%).



Mining Clinical Trial Data

To provide actionable information about worldwide clinical development activities





Clinical Trial Analysis

NCT Nur	nber			Standa	ardizatio	n of data Hits in context
Doc	Criteria	Substance	comp	Amount	Units	Hit
NCT00317499	Inclusion	ALT	≤	2	ULN	Inclusion Criteria: Subjects had so satisfy the following criteria before randomization into the study: and serum alanine transaminase (ALT) ≤ 2 times laboratory's upper limit of normal; hemoglobin ≥ 8.5 g
		Creatinine	≤	2	mg/dL	1 Inclusion Criteria: Subjects had to satisfy the following criteria before randomization into the study: cells/mm3; and serum creatinine ≤ 2 mg/dL
▼ NCT01307423	Exclusion	albumin	<		LLN	1 Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study: Exclusion Criteria: total bilirubin > ULN or albumin < lower limit of normal (LLN)
		Bilirubin	>		ULN	Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study: Exclusion Criteria: > 1.5 x ULN and total bilirubin > ULN or albumin < lower limit
	Inclusion	Bilirubin	≤	2	mg/dL	1 Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study: Total bilirubin ≤ 2 mg/dL (≤ 34 μmol/
		Creatinine	≤	132.6	µmol/L	Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study: Serum creatinine ≤ 1.5 mg/dL(≤ 132.6 µmol/L)
NCT00005660	Inclusion	Creatinine	>	3	ULN	Patients with widespread involvement (e.g. psoriasis patients with 10 percent or more of body surface area involved) or with severe, recalcitrant localized involvement with a cutaneous disorder (e.g. keratoderma palmaris et plantaris) patients with persistently abnormal (creatinine greater than 3 times the upper limit of normal) renal function tests



Clinical Trial Analysis

NCT Nur	nber			Standa	ardiza	tion o	f d	lata		Hits in	context
Doc	Criteria	Substance	comp	Amount	Units			Hit			
NCT00317499	Inclusion	ALT	≤	2	ULN		1	Inclusion Criteria: Sub randomization into the laboratory's upper lim	ojects had e study: an it of normal;	satisfy the followi d serum alanine tr hemoglobin ≥ 8.5	ng criteria before ansaminase (ALT) ≤ <mark>2</mark> times g
		Creatinine	≤	2	mg/dL		1	Inclusion Criteria: Sub randomization into the	ojects had to e study: cel	satisfy the followi ls/mm3; and seru	ng criteria before m creatinine ≤ <mark>2 mg/dL</mark>
NCT01307423	Exclusion	albumin	<		LLN		1	Inclusion Criteria: Sub study: Exclusion normal (LLN)	ojects must s teria: total	atisfy the following bilirubin > ULN o	g criteria to be enrolled in the r albumin < lower limit of
		Bilirubin	>		ULN		1	Inclusion Criteria: Sub study: Exclusion Crit lower limit	ojects must s teria: > 1.	atisfy the following 5 x ULN and total	g criteria to be enrolled in the bilirubin > <mark>ULN</mark> or albumin <
	▼ Inclusion	Bilirubin	≤	2	mg/dL		1	Inclusion Criteria: Sub study: Total bilirubi	ojects must s in ≤ <mark>2</mark> mg/dL	atisfy the following (≤ 34 µmol/	g criteria to be enrolled in the
NCT00005660	Inclu Inc	clusion	Bi	lirubir	ו	≤		2	mg/dL		criteria to be enrolled in the ol/L) s patients with 10 percent or
			In	clusic	n Cr	iteria	a:	Subjects m	ust sa	tisfy the fo	ollowing criteria
L			st	udy:	10	otal t		rubin $\leq 2 \text{ m}$	g/al (:	≤ 34 µmo	V



Workflow Integration + Clinical Trial Analysis





Mining Electronic Health Records

Diagnosis prediction from reports

Translational medicine

Analysis of treatment outcomes



Monitoring of adherence to protocols



Electronic Health Records

Identify patient information

 Need to consider context within the record, as well as the immediate sentence

age	51-year-old		
gender	female		
history		•	gastroesophageal reflux disease
			hyperlipidemia
medication	Aspirin	325	mg
	Atorvastatin Calcium	10	mg

History	Disease	Doc		Hit
history	Non-Q wave myocardial infarction	cardiology1	1	CLINICAL HISTORY: Non-Q wave myocardial infarction, unstable angina, known
history	unstable angina	<u>cardiology1</u>	1	CLINICAL HISTORY: Non-Q wave myocardial infarction, unstable angina, known history of abdominal
history	abdominal aneurysm	cardiology1	1	, unstable angina, known history of abdominal aneurysm.
family history	coronary artery disease	cardiology2	1	smoker with a markedly positive family history of coronary artery disease who has an electrocardiogram showing
history	atrial flutter	cardiology2	1	a 60-year-old with a long history of atrial flutter who has converted back to



Mining Multiple Sources

Merge information from all possible sources

Find more detailed information from a second source

Connect information across different structured and unstructured sources

Compare trends in different data sources



Delivering Diverse Data Sources



I2E OnDemand



Complete and up-to-date MEDLINE index with built in terminologies managed by Linguamatics



Structured and Unstructured Data Workflows

- Successful queries converted into regular workflows for up-to-date dashboards, alerting
- Structured resources (tabular/semantic web) augmented with information from literature



• Which genes from microarray experiment (or GWAS) show evidence of association with a disease



Conclusions

- Text Mining allows exploitation of diverse data sources e.g.
 - Scientific Literature
 - Patents
 - Social Media
- Wide range of applications, from R&D to Marketing
- Results from each source are valuable in themselves, but can also combine
 - Structured and unstructured data
 - Data from different unstructured sources

